Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early‐stage hepatocellular carcinoma: An analysis of SEER‐medicare
Authors:
- 7 June 2018
- journal article
- research article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 62 (5) , 673-681
Abstract
Introduction: For early‐stage hepatocellular carcinoma (HCC) patients, ablative strategies are potentially curative treatment options. Stereotactic body radiotherapy (SBRT) has emerged as a promising ablative therapy, although its comparison with radiofrequency ablation (RFA) remains confined to a single institution retrospective review. We sought to characterize the comparative outcomes and cost between the two treatment strategies.Methods: We conducted a secondary analysis of the Surveillance, Epidemiology, and End Results (SEER)‐Medicare linked database (2004–2011) and identified adult patients with stage I or II HCC and treated with RFA or SBRT as the initial treatment within 6 months of diagnosis. Survival analysis was conducted using Kaplan–Meier curves and multivariate Cox proportional hazard analysis. Factors associated with overall survival and 90‐day hospital admission post‐treatment were identified using propensity score (PS) adjusted multivariate analysis. We performed costs analysis and calculated incremental cost‐effectiveness ratios (ICER).Results: Four hundred and forty patients were identified, 408 treated with RFA and 32 SBRT. In the overall cohort, 90‐day hospitalization and 1‐year mortality were similar between groups but RFA patients had better overall survival (P < 0.001). Multivariate analysis showed advanced age, higher stage, decompensated cirrhosis, and treatment with SBRT (HR 1.80; 95%CI: 1.15–2.82) was associated with worse survival, but in the PS adjusted analysis, survival and costs were similar between the two groups.Conclusion: In a national cohort of early stage HCC patients, treatment with RFA vs SBRT resulted in no significant difference in survival, 90‐day hospitalization, or costs. These data highlight the need for a randomized clinical trial comparing these two modalities.Keywords
This publication has 31 references indexed in Scilit:
- Radiation Therapy for Hepatocellular CarcinomaSeminars in Radiation Oncology, 2011
- Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus InfectionGastroenterology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Safety and Efficacy of Microwave Ablation of Hepatic Tumors: A Prospective Review of a 5-Year ExperienceAnnals of Surgical Oncology, 2009
- Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies #Hepatology, 2009
- Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?Hepatology, 2007
- Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative studyJournal of Gastroenterology, 2005
- Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?Value in Health, 2004
- Prognostic prediction and treatment strategy in hepatocellular carcinomaHepatology, 2002
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994